Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 178,467 |
|
|||||
| News | - | ||||||
| Day High | 6.22 | Low High |
|||||
| Day Low | 5.71 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| ESSA Pharma Inc | EPIX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.04 | -0.65% | 6.08 | 15:30:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 6.12 | 5.71 | 6.22 | 6.08 | 6.12 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,272 | 178,467 | US$ 5.89 | US$ 1,051,002 | - | 2.56 - 11.67 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:00:00 | 10,418 | US$ 6.08 | USD |
ESSA Pharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 267.2M | 44.24M | - | 0 | -26.58M | -0.60 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
ESSA Pharma News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EPIX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.78 | 7.25 | 5.71 | 6.38 | 92,185 | -0.70 | -10.32% |
| 1 Month | 8.59 | 8.6779 | 5.71 | 7.29 | 57,829 | -2.51 | -29.22% |
| 3 Months | 8.95 | 11.67 | 5.71 | 9.31 | 124,132 | -2.87 | -32.07% |
| 6 Months | 4.06 | 11.67 | 3.8901 | 7.77 | 128,799 | 2.02 | 49.75% |
| 1 Year | 2.70 | 11.67 | 2.56 | 6.08 | 107,587 | 3.38 | 125.19% |
| 3 Years | 27.13 | 36.00 | 1.40 | 6.52 | 490,175 | -21.05 | -77.59% |
| 5 Years | 2.27 | 36.00 | 1.40 | 7.62 | 334,318 | 3.81 | 167.84% |
ESSA Pharma Description
| ESSA Pharma Inc is a pharmaceutical company. The company is in the preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. |
